RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.
The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapy.
RGCC CAMBISeq® is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best, and most effective, combinations of cancer treatments.
* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.
* RGCC is not liable for any third-party comments or claims regarding our products. For accurate and up-to-date information about our offerings, please refer to our official website: rgcc-international.com
